Autonomic Nervous System Drugs — MCQs
On this page
Which of the following is the binding site of organophosphorous compounds?
Which of the following is the binding site of organophosphorous compounds?
Which of the following drugs exhibits the phenomenon of vasomotor reversal of Dale after administration of an alpha-adrenergic blocker?
Which of the following is NOT a contraindication to the use of beta-blockers?
Suxamethonium is:
Which of the following drugs primarily increases uveo-scleral outflow?
Methacholine has maximum agonist action at which of the following cholinergic receptors?
Tolazine is used as:
Which of the following is an ionic channel?
Which beta agonist is used for stopping premature labor?
Autonomic Nervous System Drugs Indian Medical PG Practice Questions and MCQs
Question 481: Which of the following is the binding site of organophosphorous compounds?
- A. Anionic site of Acetylcholinesterase
- B. Esteric site of Acetylcholinesterase (Correct Answer)
- C. Neuromuscular receptors
- D. Plasma cholinesterase
Explanation: ### Explanation **Why Option B is Correct:** Acetylcholinesterase (AChE) is the enzyme responsible for the hydrolysis of acetylcholine. It consists of two primary domains: the **Anionic site** (which binds the quaternary ammonium group of acetylcholine) and the **Esteric site** (which contains a serine hydroxyl group responsible for the actual cleavage of the ester bond). Organophosphorus (OP) compounds act as irreversible inhibitors by forming a stable **covalent phosphate bond** with the serine hydroxyl group at the **Esteric site**. This phosphorylation prevents the enzyme from breaking down acetylcholine, leading to a cholinergic crisis. **Why Other Options are Incorrect:** * **Option A (Anionic site):** This site primarily attracts the positive charge of acetylcholine. While drugs like **Edrophonium** bind here (reversible), OP compounds specifically target the esteric site for phosphorylation. * **Option C (Neuromuscular receptors):** OP compounds do not bind directly to these receptors; instead, they cause overstimulation of these receptors by allowing acetylcholine to accumulate in the synaptic cleft. * **Option D (Plasma cholinesterase):** While OP compounds *do* bind to and inhibit plasma cholinesterase (Butyrylcholinesterase), this is not their primary mechanism of toxicity. Plasma cholinesterase levels are used clinically as a marker of exposure, but the clinical symptoms arise from the inhibition of **Acetylcholinesterase** at nerve endings. **High-Yield NEET-PG Pearls:** 1. **Aging Phenomenon:** Over time, the OP-enzyme complex loses an alkyl group, making the bond permanent. **Pralidoxime (2-PAM)**, an enzyme reactivator, must be administered *before* aging occurs to be effective. 2. **Drug of Choice:** **Atropine** is the specific physiological antagonist (blocks muscarinic effects), while Pralidoxime is the specific enzyme reactivator. 3. **Carbamates vs. OPs:** Carbamates (like Neostigmine) also bind to the esteric site but do not undergo "aging," making their inhibition reversible over hours.
Question 482: Which of the following is the binding site of organophosphorous compounds?
- A. Anionic site of Acetylcholinesterase
- B. Esteric site of Acetylcholinesterase (Correct Answer)
- C. Neuromuscular receptors
- D. Plasma cholinesterase
Explanation: **Explanation:** **Mechanism of Action (Why B is correct):** Acetylcholinesterase (AChE) is the enzyme responsible for the degradation of acetylcholine. It consists of two primary domains: the **Anionic site** (which binds the quaternary ammonium group of acetylcholine) and the **Esteric site** (which contains a serine hydroxyl group responsible for the hydrolytic cleavage). Organophosphorus (OP) compounds act as irreversible inhibitors by binding to the **Esteric site**. They phosphorylate the serine hydroxyl group, forming a stable covalent bond. This prevents the enzyme from breaking down acetylcholine, leading to a "cholinergic crisis." **Analysis of Incorrect Options:** * **Option A:** The **Anionic site** is the binding target for drugs like **Edrophonium** (reversible binding via electrostatic attraction). While acetylcholine binds to both sites, OP compounds specifically target the esteric serine. * **Option C:** OP compounds do not bind directly to **Neuromuscular receptors** (Nicotinic/Muscarinic). Instead, they cause overstimulation of these receptors by allowing acetylcholine to accumulate in the synaptic cleft. * **Option D:** While OP compounds do bind to **Plasma cholinesterase** (Butyrylcholinesterase/Pseudo-cholinesterase), this is not their primary site of toxic action. Plasma cholinesterase levels are used clinically as a marker of exposure, but the clinical symptoms of poisoning are due to the inhibition of true AChE at synapses. **High-Yield NEET-PG Pearls:** * **Aging:** Over time, the OP-enzyme bond loses an alkyl group and becomes permanent. This process is called "aging." * **Oximes (Pralidoxime/2-PAM):** These are "cholinesterase reactivators" that work by dephosphorylating the **esteric site**, but they must be administered *before* aging occurs. * **Atropine:** The specific antidote for muscarinic symptoms; it does not reactivate the enzyme but blocks the excess acetylcholine at the receptor level.
Question 483: Which of the following drugs exhibits the phenomenon of vasomotor reversal of Dale after administration of an alpha-adrenergic blocker?
- A. Adrenaline (Correct Answer)
- B. Noradrenaline
- C. Isoprenaline
- D. All of the above
Explanation: **Explanation:** **Vasomotor Reversal of Dale** refers to the phenomenon where the typical pressor (blood pressure-increasing) effect of Adrenaline is converted into a depressor (blood pressure-lowering) effect following the administration of an alpha-blocker. **1. Why Adrenaline is correct:** Adrenaline is a potent agonist of **$\alpha_1, \alpha_2, \beta_1,$ and $\beta_2$** receptors. * **Normally:** Its $\alpha_1$-mediated vasoconstriction outweighs its $\beta_2$-mediated vasodilation, resulting in a net rise in blood pressure. * **After Alpha-blockade:** The $\alpha_1$ receptors are blocked. When Adrenaline is administered, only the **$\beta_2$ receptors** in the skeletal muscle blood vessels are available for activation. This leads to unopposed vasodilation, causing the blood pressure to fall instead of rise. **2. Why other options are incorrect:** * **Noradrenaline:** It acts primarily on $\alpha_1, \alpha_2,$ and $\beta_1$ receptors with **negligible effect on $\beta_2$**. Therefore, after alpha-blockade, there is no $\beta_2$ effect to cause vasodilation; the BP simply fails to rise (it stays near baseline). * **Isoprenaline:** It is a pure $\beta$-agonist ($\beta_1 + \beta_2$). It causes a fall in BP regardless of alpha-blockade because it has no alpha action to begin with. Thus, no "reversal" occurs. **High-Yield Clinical Pearls for NEET-PG:** * **Sir Henry Dale** first demonstrated this effect using ergot alkaloids (the first alpha-blockers). * **Key Concept:** For reversal to occur, the drug must have **both** alpha (constrictor) and beta-2 (dilator) properties. * **Clinical Relevance:** In patients with Pheochromocytoma, always give alpha-blockers *before* beta-blockers to avoid a hypertensive crisis caused by unopposed alpha-mediated vasoconstriction.
Question 484: Which of the following is NOT a contraindication to the use of beta-blockers?
- A. Bradycardia
- B. Tachycardia (Correct Answer)
- C. Bronchial asthma
- D. Raynaud's disease
Explanation: **Explanation:** Beta-blockers (β-adrenoceptor antagonists) work by blocking the effects of epinephrine and norepinephrine on beta receptors. Understanding their physiological effects is key to identifying their contraindications. **Why Tachycardia is the Correct Answer:** Beta-blockers are **indicated** (used for treatment), not contraindicated, in tachycardia. By blocking $\beta_1$ receptors in the sinoatrial (SA) node, they decrease the heart rate (negative chronotropic effect). They are first-line agents for rate control in conditions like sinus tachycardia, atrial fibrillation, and thyrotoxicosis. **Why the other options are Contraindications:** * **Bradycardia (Option A):** Since beta-blockers slow the heart rate, they can worsen pre-existing bradycardia or heart block, potentially leading to cardiac arrest. * **Bronchial Asthma (Option C):** Non-selective beta-blockers block $\beta_2$ receptors in the bronchial smooth muscle, leading to bronchoconstriction. This can precipitate a life-threatening asthma attack. (Note: Cardioselective $\beta_1$ blockers are preferred if a beta-blocker is absolutely necessary). * **Raynaud’s Disease (Option D):** Blocking $\beta_2$-mediated vasodilation leaves $\alpha$-mediated vasoconstriction unopposed. This worsens peripheral vasospasm and reduces cold tolerance in patients with peripheral vascular disease. **High-Yield Clinical Pearls for NEET-PG:** * **Diabetes Mellitus:** Beta-blockers are used with caution because they mask the warning symptoms of hypoglycemia (tachycardia/tremors), though sweating (mediated by cholinergic sympathetic nerves) remains. * **Prinzmetal Angina:** They are contraindicated as they may worsen coronary vasospasm due to unopposed $\alpha$-activity. * **Cardioselectivity:** Remember the mnemonic **"A to M"** (e.g., Atenolol, Metoprolol) for $\beta_1$ selective blockers, which are safer (but not absolute) in respiratory or peripheral vascular issues.
Question 485: Suxamethonium is:
- A. A non-depolarizing muscle relaxant
- B. A depolarizing muscle relaxant (Correct Answer)
- C. A direct-acting muscle relaxant
- D. All of the above
Explanation: **Explanation:** **Suxamethonium (Succinylcholine)** is the only clinically used **depolarizing neuromuscular blocking agent**. It consists of two acetylcholine (ACh) molecules joined together. **Why Option B is Correct:** Suxamethonium acts as an agonist at the nicotinic acetylcholine receptors ($N_m$) at the neuromuscular junction. Unlike ACh, it is not metabolized by acetylcholinesterase, leading to persistent depolarization of the motor endplate. This results in initial muscle twitching (**fasciculations**) followed by flaccid paralysis because the sodium channels remain in an inactivated state, preventing further action potentials. **Why Other Options are Incorrect:** * **Option A:** Non-depolarizing relaxants (e.g., **d-Tubocurarine, Vecuronium**) are competitive antagonists. They block ACh from binding to the receptor without causing initial depolarization or fasciculations. * **Option C:** Direct-acting muscle relaxants (e.g., **Dantrolene**) act directly on the muscle fiber by inhibiting calcium release from the sarcoplasmic reticulum, rather than acting at the neuromuscular junction. **High-Yield NEET-PG Pearls:** 1. **Metabolism:** It is rapidly hydrolyzed by **Pseudocholinesterase** (Butyrylcholinesterase). Patients with atypical pseudocholinesterase experience prolonged apnea (**Suxamethonium apnea**). 2. **Side Effects:** Hyperkalemia (dangerous in burn or trauma patients), muscle soreness, and increased intraocular/intragastric pressure. 3. **Malignant Hyperthermia:** Suxamethonium is a known trigger; the antidote is **Dantrolene**. 4. **Phase II Block:** With prolonged infusion, the block may transition from depolarizing to a pattern resembling non-depolarizing blockade.
Question 486: Which of the following drugs primarily increases uveo-scleral outflow?
- A. Apraclonidine
- B. Latanoprost (Correct Answer)
- C. Timolol
- D. Brinzolamide
Explanation: **Explanation:** The management of Glaucoma involves reducing intraocular pressure (IOP) by either decreasing aqueous humor production or increasing its drainage. Drainage occurs via two pathways: the **Trabecular meshwork** (conventional) and the **Uveoscleral pathway** (unconventional). **Why Latanoprost is correct:** **Latanoprost** is a PGF2α analogue. It is the drug of choice for Open Angle Glaucoma. It works primarily by increasing the **uveoscleral outflow** of aqueous humor by relaxing the ciliary muscle and remodeling the extracellular matrix. **Analysis of Incorrect Options:** * **Apraclonidine:** An alpha-2 agonist. It primarily works by **decreasing aqueous humor production** and, to a lesser extent, increasing trabecular outflow. * **Timolol:** A non-selective beta-blocker. It is a traditional first-line agent that works solely by **decreasing aqueous humor production** from the ciliary epithelium. * **Brinzolamide:** A topical Carbonic Anhydrase Inhibitor (CAI). It reduces IOP by **decreasing the secretion** of aqueous humor (bicarbonate ions) from the ciliary body. **NEET-PG High-Yield Pearls:** * **Prost** drugs (Latanoprost, Bimatoprost, Travoprost) are the most potent drugs for lowering IOP. * **Side effects of Prostaglandins:** Increased pigmentation of the iris (heterochromia iridis), thickening/darkening of eyelashes (trichomegaly), and cystoid macular edema. * **Miotics (Pilocarpine)** increase **trabecular** outflow by contracting the ciliary muscle. * **Drug of choice for Acute Angle Closure Glaucoma:** IV Acetazolamide/Mannitol (to rapidly lower pressure before surgery).
Question 487: Methacholine has maximum agonist action at which of the following cholinergic receptors?
- A. M1
- B. M2 (Correct Answer)
- C. M3
- D. M4
Explanation: **Explanation:** Methacholine is a synthetic choline ester and a non-selective muscarinic agonist. While it acts on all muscarinic receptors, it exhibits a **predominant effect on M2 receptors**, particularly those located in the heart. **Why M2 is the correct answer:** Methacholine is chemically related to acetylcholine but possesses a methyl group on the beta-carbon. This modification makes it more resistant to acetylcholinesterase and confers a high degree of selectivity for muscarinic receptors over nicotinic receptors. Among the muscarinic subtypes, its most potent clinical and physiological impact is seen on **M2 receptors** (located in the SA and AV nodes), where it causes significant bradycardia and decreased conduction velocity. **Analysis of Incorrect Options:** * **M1 (Option A):** These are primarily located in the CNS and gastric glands. While methacholine can bind to them, its affinity and clinical manifestation are significantly lower than its cardiac (M2) effects. * **M3 (Option C):** These are found in smooth muscles (bronchi, bladder) and exocrine glands. Although methacholine causes bronchoconstriction via M3 receptors (used in the "Methacholine Challenge Test"), its maximal agonist potency is traditionally associated with the M2 subtype in pharmacological profiling. * **M4 (Option D):** These are primarily located in the CNS. Methacholine has negligible clinical action at these sites compared to peripheral M2 and M3 receptors. **High-Yield Clinical Pearls for NEET-PG:** 1. **Methacholine Challenge Test:** Used to diagnose **Bronchial Asthma** by identifying airway hyperreactivity. A positive test is a 20% reduction in FEV1. 2. **Structure-Activity Relationship:** The beta-methyl group in methacholine is responsible for its **muscarinic selectivity** and resistance to degradation. 3. **Contraindications:** Always avoid methacholine in patients with known bradycardia, heart block, or active peptic ulcer disease due to its potent M2 and M3 effects.
Question 488: Tolazine is used as:
- A. A thrombin inhibitor in peripheral angiography
- B. A vasodilator in treating coronary artery stenosis during angioplasty procedures (Correct Answer)
- C. A vasoconstrictor in treatment of varices
- D. An antispasmodic during biliary spasm
Explanation: **Explanation:** **Tolazoline** (often referred to as Tolazine in clinical contexts) is a non-selective **alpha-adrenergic receptor antagonist** with additional histamine-like and cholinergic properties. **Why Option B is Correct:** Tolazoline acts as a potent **direct-acting vasodilator**. In interventional cardiology, it is primarily used during coronary angioplasty to treat or prevent **"no-reflow" phenomena** and coronary vasospasms. By blocking alpha-1 receptors on vascular smooth muscle, it induces relaxation of the coronary arteries, improving distal blood flow and reducing stenosis caused by spasm. **Analysis of Incorrect Options:** * **Option A:** Tolazoline has no anticoagulant or antiplatelet properties; it does not inhibit thrombin. Thrombin inhibitors include drugs like Heparin or Bivalirudin. * **Option C:** Tolazoline is a vasodilator, not a vasoconstrictor. Vasoconstrictors used for varices include Terlipressin or Somatostatin. * **Option D:** While it has some cholinergic effects, it is not used as a biliary antispasmodic. Drugs like Hyoscine or Drotaverine are preferred for this purpose. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Non-selective α-blocker (α1 and α2). * **Other Uses:** Historically used for **Persistent Pulmonary Hypertension of the Newborn (PPHN)**, though it has largely been replaced by inhaled Nitric Oxide. * **Side Effects:** Can cause GI stimulation (due to histamine-like action), leading to diarrhea and exacerbation of peptic ulcers. * **Key Distinction:** Do not confuse Tolazoline (α-blocker) with **Hydralazine** (direct vasodilator) or **Xylometazoline** (α-agonist/decongestant).
Question 489: Which of the following is an ionic channel?
- A. $\alpha$1 receptors
- B. $\beta$1 receptors
- C. Nicotinic cholinergic receptors (Correct Answer)
- D. Muscarinic cholinergic receptors
Explanation: ### Explanation The correct answer is **C. Nicotinic cholinergic receptors**. **1. Why Nicotinic receptors are the correct answer:** Receptors are broadly classified into four types based on their signaling mechanism. **Nicotinic cholinergic receptors (N-receptors)** belong to the **Ionotropic receptor** family (Ligand-gated ion channels) [1], [2]. When acetylcholine binds to these receptors, it causes a conformational change that opens a central pore, allowing the rapid influx of sodium ($Na^+$) and sometimes calcium ($Ca^{2+}$) ions [1], [4], [5]. This leads to immediate depolarization of the cell membrane. They are found at the neuromuscular junction (Nm) and autonomic ganglia (Nn) [4]. **2. Why the other options are incorrect:** * **$\alpha$1 and $\beta$1 receptors (Options A & B):** These are adrenergic receptors. All adrenergic receptors ($\alpha$ and $\beta$) are **G-Protein Coupled Receptors (GPCRs)**, also known as metabotropic receptors. $\alpha$1 acts via the $G_q$ pathway (IP3/DAG), while $\beta$1 acts via the $G_s$ pathway (cAMP). * **Muscarinic cholinergic receptors (Option D):** Unlike nicotinic receptors, muscarinic receptors (M1–M5) are **GPCRs** [1], [2]. They do not form a channel themselves but use second messengers to influence ion channels or enzymes. **3. High-Yield Clinical Pearls for NEET-PG:** * **Fastest Receptors:** Ionotropic receptors (Nicotinic) are the fastest (milliseconds), while Nuclear receptors are the slowest (hours to days) [1]. * **Structure:** Nicotinic receptors are pentameric (composed of 5 subunits) [3], [4], [5]. * **Specific Blockers:** **Curare** (d-tubocurarine) blocks Nm receptors at the skeletal muscle, while **Hexamethonium** is a classic blocker of Nn receptors at the ganglia. * **Mnemonics for GPCRs:** * $G_q$: "HAVe 1 M&M" ($H_1, \alpha_1, V_1, M_1, M_3$) * $G_i$: "MAD 2s" ($M_2, \alpha_2, D_2$) * $G_s$: All $\beta$ receptors ($\beta_1, \beta_2, \beta_3$)
Question 490: Which beta agonist is used for stopping premature labor?
- A. Carvedilol
- B. Terbutaline (Correct Answer)
- C. Pindolol
- D. Nadolol
Explanation: **Explanation:** The correct answer is **Terbutaline**. **1. Why Terbutaline is correct:** Terbutaline is a **selective $\beta_2$-adrenergic agonist**. In the context of obstetrics, it acts as a **tocolytic** agent. Stimulation of $\beta_2$ receptors in the uterine smooth muscle (myometrium) increases intracellular cAMP, which leads to the relaxation of the uterus. This mechanism is used clinically to delay or stop premature labor (tocolysis), providing a window to administer corticosteroids for fetal lung maturity. **2. Why the other options are incorrect:** * **Carvedilol (A):** This is a non-selective $\beta$-blocker with additional $\alpha_1$-blocking activity. It is used in the management of heart failure and hypertension, not for uterine relaxation. * **Pindolol (C):** This is a non-selective $\beta$-blocker with **Intrinsic Sympathomimetic Activity (ISA)**. It is used for hypertension and would actually oppose uterine relaxation. * **Nadolol (D):** This is a long-acting non-selective $\beta$-blocker primarily used for hypertension, angina, and prophylaxis of migraine or variceal bleeding. **3. High-Yield Clinical Pearls for NEET-PG:** * **Other Tocolytics:** While Terbutaline is a classic $\beta_2$ agonist for this purpose, **Ritodrine** is another specific $\beta_2$ agonist developed for tocolysis. However, **Nifedipine** (Calcium Channel Blocker) and **Atosiban** (Oxytocin antagonist) are now often preferred due to fewer side effects. * **Side Effects:** A high-yield side effect of $\beta_2$ agonists used in labor is **maternal tachycardia**, palpitations, and potential **pulmonary edema**. * **Metabolic Effect:** $\beta_2$ agonists can cause **hypokalemia** and **hyperglycemia** (due to glycogenolysis).
Practice by Chapter
Cholinergic Agonists
Practice Questions
Cholinergic Antagonists
Practice Questions
Adrenergic Agonists
Practice Questions
Adrenergic Antagonists
Practice Questions
Ganglionic Agents
Practice Questions
Neuromuscular Blocking Agents
Practice Questions
Autonomic Drugs in Ophthalmology
Practice Questions
Autonomic Drugs in Cardiovascular Disease
Practice Questions
Autonomic Drugs in Respiratory Disease
Practice Questions
Autonomic Drugs in Urological Disorders
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free